● Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Condition: Systemic Sclerosis · Idiopathic Inflammatory Myopathies · Antineutrophil Cytoplasmic Antibody-Associated Vasculitis · Sponsor: Nkarta, Inc.

PhasePhase 1/Phase 2

Planned participants240

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

This description comes directly from the study's public registry record.

Talk to the study team

Nkarta Central Contact · Only use email · clinicaltrials@nkartatx.com

Always discuss trial participation with your own doctor first.

Locations (17)

Nkarta Investigational Site	Orange, California, United States	Recruiting
Nkarta Investigational Site	Gainesville, Florida, United States	Recruiting
Nkarta Investigational Site	Miami, Florida, United States	Withdrawn
Nkarta Investigational Site	Plantation, Florida, United States	Recruiting
Nkarta Investigational Site	Chicago, Illinois, United States	Recruiting
Nkarta Investigational Site	Fairway, Kansas, United States	Recruiting
Nkarta Investigational Site	Ann Arbor, Michigan, United States	Recruiting
Nkarta Investigational Site	Minneapolis, Minnesota, United States	Recruiting
Nkarta Investigational Site	Hackensack, New Jersey, United States	Recruiting
Nkarta Investigational Site	Summit, New Jersey, United States	Recruiting
Nkarta Investigational Site	New York, New York, United States	Recruiting
Nkarta Investigational Site	Stony Brook, New York, United States	Recruiting

+ 5 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06733935